Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Rating of “Hold” by Brokerages

Posted by on May 21st, 2026

Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) has been given a consensus rating of “Hold” by the five research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $5.40.

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Friday, April 24th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $8.00 to $2.00 in a report on Thursday, January 29th.

Get Our Latest Stock Report on Fractyl Health

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Fractyl Health by 23.5% in the 3rd quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock worth $141,000 after buying an additional 16,856 shares during the period. Jane Street Group LLC bought a new position in Fractyl Health in the 2nd quarter worth approximately $31,000. FNY Investment Advisers LLC bought a new position in Fractyl Health in the 3rd quarter worth approximately $31,000. Jump Financial LLC bought a new position in Fractyl Health in the 4th quarter worth approximately $57,000. Finally, Scientech Research LLC acquired a new stake in shares of Fractyl Health during the 3rd quarter worth approximately $49,000.

Fractyl Health Stock Up 12.8%

GUTS opened at $0.92 on Friday. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03. The business has a 50-day moving average of $0.58 and a 200-day moving average of $1.12. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The company has a market capitalization of $146.16 million, a PE ratio of -0.71 and a beta of 2.11.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. Equities research analysts forecast that Fractyl Health will post -0.6 EPS for the current fiscal year.

Fractyl Health Company Profile

(Get Free Report)

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

Read More

Analyst Recommendations for Fractyl Health (NASDAQ:GUTS)

Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.